403 results on '"Antonucci, Emilia"'
Search Results
2. The use of reduced DOAC doses in atrial fibrillation patients does not always lead to good anticoagulation levels and avoid adverse events
3. Can the Charlson comorbidity index help to guide DOAC dosing in patients with atrial fibrillation and improve the efficacy and safety of treatment? A subanalysis of the MAS study
4. More early bleeds associated with high baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study
5. Machine learning approach for prediction of outcomes in anticoagulated patients with atrial fibrillation
6. DOACs use in extreme body-weighted patients: results from the prospective START-register
7. Thrombotic events associated with low baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study
8. Renin‐angiotensin-aldosterone system inhibitors and mortality risk in elderly patients with atrial fibrillation. Insights from the nationwide START registry
9. Statins under-treatment and mortality in patients with atrial fibrillation. Insights from the nationwide START registry
10. Venous thromboembolism secondary to hospitalization for COVID-19: patient management and long-term outcomes
11. D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study
12. Low in-hospital mortality rate in patients with COVID-19 receiving thromboprophylaxis: data from the multicentre observational START-COVID Register
13. MORE EARLY BLEEDS ASSOCIATED WITH HIGH BASELINE DIRECT ORAL ANTICOAGULANT LEVELS IN ATRIAL FIBRILLATION: THE MAS STUDY
14. Corrigendum to “Machine learning approach for prediction of outcomes in anticoagulated patients with atrial fibrillation” [International Journal of Cardiology 407 (2024) 132088]
15. Patients with antiphospholipid syndrome and a first venous or arterial thrombotic event: clinical characteristics, antibody profiles and estimate of the risk of recurrence
16. Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry
17. Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs
18. Design and rationale of a randomized, placebo-controlled trial on the efficacy and safety of sulodexide for extended treatment in elderly patients after a first venous thromboembolism
19. Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry)
20. Patients with isolated pulmonary embolism in comparison to those with deep venous thrombosis. Differences in characteristics and clinical evolution
21. Very elderly patients with venous thromboembolism on oral anticoagulation with VKAs or DOACs: Results from the prospective multicenter START2-Register Study
22. Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants
23. Inappropriate Underdosing of Direct Oral Anticoagulants in Atrial Fibrillation Patients: Results from the START2-AF Registry.
24. LOW LEVELS OF DIRECT ORAL ANTICOAGULANTS AT STEADY STATE IN ATRIAL FIBRILLATION PATIENTS WHO LATER DEVELOP THROMBOTIC COMPLICATIONS; THE PROSPECTIVE MAS (MEASURE AND SEE) STUDY
25. Statins under-treatment and mortality in patients with atrial fibrillation. Insights from the nationwide START registry
26. Descriptive analysis of patients positive for anti-phospholipid antibodies included in two Italian registries
27. Mechanical prosthetic heart valves: Quality of anticoagulation and thromboembolic risk. The observational multicenter PLECTRUM study
28. Impact of Chronic Renal Failure on Ischemic and Bleeding Events at 1 Year in Patients With Acute Coronary Syndrome (from the Multicenter START ANTIPLATELET Registry)
29. Comparison of HAS-BLED and HAS-BED Versus CHADS2 and CHA2DS2VASC Stroke and Bleeding Scores in Patients With Atrial Fibrillation
30. Long-Term Outcomes in Two-Year Follow-Up after Primary Treatment in Patients with a Prior Venous Thromboembolic Event: A Prospective, Observational, Real-Life Study.
31. Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry
32. Venous Thromboembolism in Women of Childbearing Age: Insights from the START Registry
33. VENOUS THROMBOEMBOLISM SECONDARY TO HOSPITALIZATION FOR COVID-19 DISEASE: PATIENT MANAGEMENT AND LONG-TERM OUTCOMES
34. Warfarin prescription in patients with nonvalvular atrial fibrillation and one non–gender‐related risk factor (CHA2DS2VASc 1 or 2): A treatment dilemma
35. Obstetrical history of women with cerebral vein thrombosis: outcome of the pregnancies before and after the thrombotic event
36. Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago
37. Evaluation of Coaguchek®Pro II coagulation testing device performance to assess direct oral anticoagulant action. The DOAC-CHECK study
38. Residual perfusion defects in patients with pulmonary embolism are related to impaired fibrinolytic capacity
39. D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study
40. Cardiovascular risk stratification in patients with non-valvular atrial fibrillation: the 2MACE score
41. Quality of warfarin anticoagulation in adults with short bowel syndrome on home parenteral nutrition
42. Major bleedings in mechanical prosthetic heart valves patients on Vitamin K antagonist treatment. Data from the PLECTRUM Study
43. Gender differences of bleeding and stroke risk in very Old atrial fibrillation patients on VKA treatment: Results of the EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics)
44. Hemostatic Complications in Renal Transplantation
45. Intracranial hemorrhage recurrence on vitamin K antagonist: severity of the first episode and HASBLED score fail to identify high-risk patients from the CHIRONE study
46. Management of anticoagulation in atrial fibrillation patients in Italy: insight from the Atrial Fibrillation-Survey on Anticoagulated Patients Register (AF-START).
47. Risk of bleeding in low-risk atrial fibrillation patients on warfarin waiting for elective cardioversion
48. Thromboembolic Complications in COVID-19 Patients Hospitalized in Italian Ordinary Wards: Data from the Multicenter Observational START-COVID Register
49. Bleeding and Stroke Risk in a Real-world Prospective Primary Prevention Cohort of Patients With Atrial Fibrillation
50. Rationale and design of a study on D-dimer use to stratify patients after a first unprovoked venous thromboembolism for their risk of recurrence: extended low-dose Apixaban given only to patients with positive D-dimer results
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.